Previous 10 | Next 10 |
-- RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial -- -- CB-010 is the 1 st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout -- BERKELEY, CA, Nov. 29, 2022 (GLOBE N...
-- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is engineered with a differentiated immune cloaking strategy, designed to enhance persistence -- -- CB-011 is Caribou’s second off-the-shelf CAR-T cell ...
Caribou Bioscience press release ( NASDAQ: CRBU ): Q3 GAAP EPS of -$0.44 beats by $0.04 . Revenue of $3.3M (-17.1% Y/Y) misses by $0.4M . For further details see: Caribou Bioscience GAAP EPS of -$0.44 beats by $0.04, revenue of $3.3M misses by $0.4M
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong financial position of $342.6 million in cash, cash equivalents, and marketable securi...
BERKELEY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that a trial-in-progress abstract for the Company’s ongoing ANTLER Phase 1 clinical trial evaluating...
BERKELEY, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of a case report for long-term follow up on the first patient dosed in its ANTLER Phase 1 ...
Summary Trading activity on the Tradeweb European ETF marketplace amounted to EUR 49.7 billion in September. Total consolidated U.S. ETF notional value traded in September 2022 reached USD 51 billion. During September 2, 113 unique tickers traded on the Tradeweb U.S. ETF marke...
Summary Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable. If a higher dose, now ongoing, produces a durable response, this stock will likely go up. Caribou Biosciences ( CRBU ), founde...
Summary Stanley Druckenmiller’s 13F portfolio value decreased from $2.65B to $1.63B this quarter. Duquesne added Eli Lilly and CrowdStrike while reducing Microsoft, Freeport-McMoRan, and Teck Resources. They also dropped Amazon.com. The top three positions are at ~34% o...
BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 17 th ...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...